Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests better way to open blocked leg arteries

NCT ID NCT03206762

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two ways to treat blocked leg arteries in 47 people with leg pain when walking. One group had a special device to remove plaque (atherectomy) followed by a drug-coated balloon, while the other had standard balloon angioplasty followed by the same drug-coated balloon. The goal was to see which approach better kept arteries open and reduced the need for repeat procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

47 people

The number who actually took part.

Started

Mar 2018

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subject must meet all of the following general inclusion criteria. 1. Has a Rutherford Clinical Category of 2 - 4. 2. Is willing and capable of complying with all follow-up evaluations at the specified times (including an angiogram at the 1-year follow-up visit). 3. Is ≥ 18 years old. 4. Is able and willing to provide written informed consent prior to study specific procedures. Angiographic Inclusion Criteria: Subject must meet all of the following angiographic inclusion criteria. Unless otherwise specified, the Investigator performing the procedure bases all angiographic inclusion criteria on visual determination at the time of the procedure. 1. Has evidence at the target lesion of ≥ 70% de novo stenosis of a. ≥ 10 cm length, or b. any chronic total occlusion (\> 1 month by history or known by conventional or CT angiography or arterial duplex ultrasound) in the SFA (at least 1 cm from the bifurcation of the profunda) and/or popliteal artery, or 3. at least grade 2 or higher calcification as defined by the peripheral arterial calcium scoring system (PACCS)26 2. Has evidence of at least one runoff vessel to the ankle/foot of the limb to be treated that does not have significant (\< 70%) stenosis during the index procedure. 3. Has a reference vessel diameter of 4 - 7 mm. 4. Has a target lesion an exchangeable guidewire can cross via the true lumen (without using a re-entry device or a subintimal approach). General Exclusion Criteria: The subject must not meet any of the following general exclusion criteria. 1. Has one or more of the contraindications listed in the JetStream or Ranger IFUs. 2. Has a contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used (that cannot be reasonably substituted). 3. Is expected to require cilostazol (Pletal) during the one-year follow-up period. 4. Has a hypersensitivity to contrast material that cannot be adequately pretreated. 5. Has known hypersensitivity to treatment device materials including paclitaxel or nitinol. 6. Has known uncontrollable hypercoagulable condition, or refuses blood transfusion. 7. Has life expectancy of less than 24 months. 8. Is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing. 9. Has surgical or endovascular procedure of the target vessel within 30 days prior to the index procedure. 10. Has any planned surgical intervention (requiring hospitalization) or endovascular procedure within 30 days after the index procedure. 11. Is currently participating in an investigational drug or another device study that may clinically interfere with the study outcomes. 12. Has any co-morbid condition that in the judgment of the physician precludes safe percutaneous intervention. 13. Has had a previous peripheral bypass affecting the target vessel (allowable for physician to pass through bypass graft in aorta-iliac region to get to the target lesion). 14. Has chronic renal insufficiency (eGFR \< 30 ml/min or creatinine ≥ 2.5 including dialysis patients). 15. Has planned laser, cryo, TurboHawk or any other treatment except study treatment within 30 days after the index procedure. 16. Has had superficial thrombophlebitis or deep venous thrombus within 30 days prior to index procedure. 17. Has had a stroke within 3 months prior to index procedure. 18. Has had a myocardial infarction within 1 month prior to index hospitalization 19. Has history of significant gastrointestinal bleeding in the past 2 months prior to index procedure, or any history of hemorrhagic diathesis. 20. Has a known or suspected systemic infection at the time of the index procedure. 21. Patients with ipsilateral Iliac and CFA disease are allowed in the study but these lesions have to be treated successfully first (\<30% residual) before patient can be enrolled. Treatment as per investigator's preference. 22. Aneurysm located in the target vessel or aneurysmal vessel Angiographic Exclusion Criteria: The subject must not meet any of the following angiographic exclusion criteria. The Investigator performing the procedure bases all angiographic exclusion criteria on visual determination at the time of the procedure. 1. Has \< 70% stenosis prior to treatment of the target lesion. 2. Has in-stent restenosis of the target lesion. 3. Has an acute intraluminal thrombus within the target lesion. 4. Has an aneurysmal target vessel 5. Patient has already been enrolled in the study or any other study that by the investigator judgment may interfere with the outcome of this trial 6. Has two or more lesions that require treatment in the target vessel. Lesions have to be separated by \> 5 cm in order to be considered different lesions. Only one lesion per target vessel can be enrolled during the index procedure 7. Has disease that precludes safe advancement of the JS device to the target lesion. 8. P3 segments of the popliteal vessel.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Midwest Cardiovascular Research Foundation

    Davenport, Iowa, 52803, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.